IBDEI1NV ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26528,0)
 ;;=H0015^^108^1248^4^^^^1
 ;;^UTILITY(U,$J,358.3,26528,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26528,1,2,0)
 ;;=2^H0015
 ;;^UTILITY(U,$J,358.3,26528,1,3,0)
 ;;=3^ALCOH AND/OR DRUG SVCS;INTEN OPT TX,PER DAY
 ;;^UTILITY(U,$J,358.3,26529,0)
 ;;=G0176^^108^1248^1^^^^1
 ;;^UTILITY(U,$J,358.3,26529,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26529,1,2,0)
 ;;=2^G0176
 ;;^UTILITY(U,$J,358.3,26529,1,3,0)
 ;;=3^ACTIVITY TX R/T CARE & TX OF DISABILING MH PROBLEMS,45+ MIN
 ;;^UTILITY(U,$J,358.3,26530,0)
 ;;=G0177^^108^1248^32^^^^1
 ;;^UTILITY(U,$J,358.3,26530,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26530,1,2,0)
 ;;=2^G0177
 ;;^UTILITY(U,$J,358.3,26530,1,3,0)
 ;;=3^MH EDUC & TRAIN SVCS R/T CARE & TX OF DISABILING MH PROBLEM,45+ MIN
 ;;^UTILITY(U,$J,358.3,26531,0)
 ;;=Q3014^^108^1248^59^^^^1
 ;;^UTILITY(U,$J,358.3,26531,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26531,1,2,0)
 ;;=2^Q3014
 ;;^UTILITY(U,$J,358.3,26531,1,3,0)
 ;;=3^TELEHEALTH FACILITY FEE
 ;;^UTILITY(U,$J,358.3,26532,0)
 ;;=99078^^108^1248^18^^^^1
 ;;^UTILITY(U,$J,358.3,26532,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26532,1,2,0)
 ;;=2^99078
 ;;^UTILITY(U,$J,358.3,26532,1,3,0)
 ;;=3^GROUP HEALTH EDUCATION/COUNSELING
 ;;^UTILITY(U,$J,358.3,26533,0)
 ;;=S9446^^108^1248^41^^^^1
 ;;^UTILITY(U,$J,358.3,26533,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26533,1,2,0)
 ;;=2^S9446
 ;;^UTILITY(U,$J,358.3,26533,1,3,0)
 ;;=3^PT EDUCATION NOS,GROUP NON-PHYS
 ;;^UTILITY(U,$J,358.3,26534,0)
 ;;=S9445^^108^1248^42^^^^1
 ;;^UTILITY(U,$J,358.3,26534,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26534,1,2,0)
 ;;=2^S9445
 ;;^UTILITY(U,$J,358.3,26534,1,3,0)
 ;;=3^PT EDUCATION NOS,INDIV NON-PHYS
 ;;^UTILITY(U,$J,358.3,26535,0)
 ;;=98960^^108^1248^54^^^^1
 ;;^UTILITY(U,$J,358.3,26535,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26535,1,2,0)
 ;;=2^98960
 ;;^UTILITY(U,$J,358.3,26535,1,3,0)
 ;;=3^SELF-MGMT EDUC/TRAIN,INDIV,EA 30 MIN
 ;;^UTILITY(U,$J,358.3,26536,0)
 ;;=96127^^108^1248^8^^^^1
 ;;^UTILITY(U,$J,358.3,26536,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26536,1,2,0)
 ;;=2^96127
 ;;^UTILITY(U,$J,358.3,26536,1,3,0)
 ;;=3^BRIEF EMOTION/BEHAV ASSMT W/ SCORE & DOCUM
 ;;^UTILITY(U,$J,358.3,26537,0)
 ;;=G0175^^108^1248^29^^^^1
 ;;^UTILITY(U,$J,358.3,26537,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26537,1,2,0)
 ;;=2^G0175
 ;;^UTILITY(U,$J,358.3,26537,1,3,0)
 ;;=3^INTERDISC CONF W/ PT,MINIMUM 3 STAFF
 ;;^UTILITY(U,$J,358.3,26538,0)
 ;;=H0006^^108^1248^17^^^^1
 ;;^UTILITY(U,$J,358.3,26538,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26538,1,2,0)
 ;;=2^H0006
 ;;^UTILITY(U,$J,358.3,26538,1,3,0)
 ;;=3^ETOH/DRUG CASE MGMT
 ;;^UTILITY(U,$J,358.3,26539,0)
 ;;=H0047^^108^1248^58^^^^1
 ;;^UTILITY(U,$J,358.3,26539,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26539,1,2,0)
 ;;=2^H0047
 ;;^UTILITY(U,$J,358.3,26539,1,3,0)
 ;;=3^SUBSTANCE USE SVCS,NOS
 ;;^UTILITY(U,$J,358.3,26540,0)
 ;;=H0039^^108^1248^6^^^^1
 ;;^UTILITY(U,$J,358.3,26540,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26540,1,2,0)
 ;;=2^H0039
 ;;^UTILITY(U,$J,358.3,26540,1,3,0)
 ;;=3^ASSERTIVE COMMUNITY TX,F2F,PER 15 MIN
 ;;^UTILITY(U,$J,358.3,26541,0)
 ;;=H0040^^108^1248^5^^^^1
 ;;^UTILITY(U,$J,358.3,26541,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26541,1,2,0)
 ;;=2^H0040
 ;;^UTILITY(U,$J,358.3,26541,1,3,0)
 ;;=3^ASSERTIVE COMMUNITY TX PROG,PER DIEM
 ;;^UTILITY(U,$J,358.3,26542,0)
 ;;=H0036^^108^1248^10^^^^1
